Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits
- Details
- Category: Pfizer
Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus
New Structure of Business Operations for a Global Pharmaceutical Company
- Details
- Category: Takeda
As part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture".
PATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition
- Details
- Category: Abbott
PATH, Abbott (NYSE: ABT) and the Abbott Fund announced a partnership to address malnutrition by advancing the rice fortification market in India. Currently, 200 million people suffer from hunger and malnutrition in India, more than any other country in the world.
ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership
- Details
- Category: Bristol-Myers Squibb
ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company (NYSE: BMY) announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.
Sanofi net sales up 10.1% and Business net income up 4.1% at CER
- Details
- Category: Sanofi
Sanofi's net sales in the third quarter of 2011 were €8,753 million, an increase of 5.0% on a reported basis. Exchange rate movements had a negative effect of 5.1 percentage points, mainly due to a less favorable euro/U.S. dollar parity.
Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
- Details
- Category: Eli Lilly and Company
To sustain medical innovation, the FDA must accelerate the adoption of a Benefit-Risk framework to inform decision-making in the regulatory process, said John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY).
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Details
- Category: Abbott
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
More Pharma News ...
- Pfizer Reports Third-Quarter 2011 Results
- Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
- Pfizer Completes Acquisition Of Icagen
- Shire continued strong product sales performance in Q3
- After a good third quarter: Bayer confirms Group outlook
- Bristol-Myers Squibb Delivers Strong Third Quarter
- AstraZeneca Third Quarter Results